BiotechTube

latanoprost/timolol

ApprovedCompleted
2 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Eye Diseases

Conditions

Eye Diseases, Glaucoma, Open-Angle, Glaucoma

Trial Timeline

May 1, 2009 → Sep 1, 2012

NCT ID
NCT00913029

About latanoprost/timolol

latanoprost/timolol is a approved stage product being developed by Glaukos for Eye Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT00913029. Target conditions include Eye Diseases, Glaucoma, Open-Angle, Glaucoma.

What happened to similar drugs?

20 of 20 similar drugs in Eye Diseases were approved

Approved (20) Terminated (2) Active (0)
✅Infliximab + Infliximab + InfliximabCelltrionApproved
✅Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved
✅Sarpogrelate SR + SarpogrelateYuhanApproved
✅Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)Daiichi SankyoApproved
✅Regadenoson + PlaceboAstellas PharmaApproved
✅mouse nerve growth factorSun PharmaceuticalApproved
✅DesidustatZydus LifesciencesApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00913029ApprovedCompleted

Competing Products

20 competing products in Eye Diseases

See all competitors
ProductCompanyStageHype Score
polypill + Usual cardiovascular medicationsDr. Reddy's LaboratoriesPhase 3
37
raloxifene + placeboEli LillyPhase 3
40
LatozinemabAlectorPhase 3
22
RLYB116 for InjectionRallybioPhase 1
19
Prasugrel (CS-747) + ClopidogrelEli LillyPhase 2
35
Infliximab + Infliximab + InfliximabCelltrionApproved
50
CT-P13CelltrionPhase 3
36
Subcutaneous infliximab CT-P13 Remsima®SCCelltrionPre-clinical
22
Lesigercept + PlaceboYuhanPhase 2
42
Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved
43
Sarpogrelate SR + SarpogrelateYuhanApproved
43
Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)Daiichi SankyoApproved
43
Mirabegron + Solifenacin succinate + PlaceboAstellas PharmaPhase 2
35
Mirabegron + Solifenacin succinateAstellas PharmaPhase 3
40
ATG (Fresenius Biotech)Astellas PharmaPhase 2
27
TamuslosinAstellas PharmaPhase 3
40
LexiscanAstellas PharmaPhase 2
35
mirabegron 25 mg + mirabegron 50 mg + solifenacin 5 mg + solifenacin 10 mg + mirabegron 25 mg matching placebo + mirabegron 50 mg matching placebo + solifenacin 5 mg matching placebo + solifenacin 10 mg matching placeboAstellas PharmaPhase 3
40
Tacrolimus + Cyclosporine + Mycophenolate mofetil + Methylprednisolone + PrednisoneAstellas PharmaPhase 3
40
TamusulosinAstellas PharmaPhase 3
40